BioRegenx Inc (BRGX)
BioRegenx Inc is a common stock listing on OTC Markets for a company focused on medical testing equipment and science-based nutritional products. The business develops, manufactures, and sells wellness-related products in the United States and internationally, including Endocalyx Pro and other supplements under the MyBodyRx brand, GlycoCheck software, hydrogen water products, and a range of devices such as pulsed electro-magnetic field systems and StimaWELL and ReLounge muscle stimulation products. It also develops digital tools, including the TruScan.Ai and VitalWellness applications, a social media content management platform with an interactive search engine, and the DocSun AI Engine, which combines heartbeat detection and blood-flow tracking technologies. The company says it sells through a direct-selling channel to health professionals and research organizations and is based in Chattanooga, Tennessee.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-BRGX
|
$0.0058
|
-23.7% Downside
|
Overvalued
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-5.7x
|
-1.6x
|
4.2x
|
7.384 M
|
9.504 M
|
22.7%
|
26.6%
|
-165.3
|
—
|
-1.4%
|
